NCT05208177 2025-08-22
A Study of SHR-1802 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
Clinical Trials
11 trialsNCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04346381 2023-09-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04479904 2021-06-22
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT02356991 2019-11-04
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Suspended
NCT01392235 2019-01-22
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01994213 2019-01-22
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT01829841 2018-05-03
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01762293 2018-04-18
A Study of Famitinib in Patients With Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT02336724 2018-04-17
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown